Immunovant, Inc. - Common Stock, par value $0.0001 per share (IMVT)

Historical Holders from Q4 2019 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
IMVT on Nasdaq
Shares outstanding
202,731,676
Price per share
$25.42
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
95,141,975
Total reported value
$1,533,691,024
% of total 13F portfolios
0.01%
Share change
-1,433,523
Value change
-$22,917,430
Avg buy value change
+0%
Avg sell value change
-0%
Number of holders
181
Price from insider filings
$26.92
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Immunovant, Inc. - Common Stock, par value $0.0001 per share (IMVT) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Roivant Sciences Ltd. 56% -1.8% $2,812,776,314 +$413,666,650 113,327,007 +17% Roivant Sciences Ltd. 12 Dec 2025
FMR LLC 8.4% -17% $237,440,423 -$37,858,433 14,729,555 -14% FMR LLC 30 Sep 2025
Deep Track Capital, LP 5.6% $144,590,000 9,500,000 Deep Track Capital, LP 19 Mar 2025
As of 30 Sep 2025, Immunovant, Inc. - Common Stock, par value $0.0001 per share (IMVT) has 181 institutional shareholders filing 13F forms. They hold 95,141,975 shares. of 202,731,676 outstanding shares (47%) .

Top 25 institutional shareholders own 41% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
FMR LLC 7.3% 14,729,555 -21% 0.01% $237,440,423
Deep Track Capital, LP 4.8% 9,728,845 +2.4% 4.4% $156,828,981
VANGUARD GROUP INC 3.4% 6,826,810 -2.8% 0% $110,048,178
ARMISTICE CAPITAL, LLC 2.9% 5,836,000 +12% 3% $94,076,320
BlackRock, Inc. 2.8% 5,738,236 -1.9% 0% $92,500,364
BAKER BROS. ADVISORS LP 2.7% 5,457,881 0% 0.64% $87,981,042
T. Rowe Price Investment Management, Inc. 2.5% 5,164,698 -25% 0.05% $83,255,000
Point72 Asset Management, L.P. 1.7% 3,442,078 +3.2% 0.12% $55,486,307
STATE STREET CORP 1.4% 2,892,618 +2.2% 0% $46,629,002
Two Seas Capital LP 1.4% 2,762,040 +23% 2.7% $44,524,085
Alpine Global Management, LLC 1.4% 2,754,731 +4.9% 11% $44,406,264
ADAR1 Capital Management, LLC 1.1% 2,241,753 +319% 3.6% $36,137,058
MORGAN STANLEY 0.97% 1,959,025 -15% 0% $31,579,490
GEODE CAPITAL MANAGEMENT, LLC 0.89% 1,801,649 -1.3% 0% $29,047,160
STEMPOINT CAPITAL LP 0.78% 1,589,580 +22% 5.2% $25,624,030
PERCEPTIVE ADVISORS LLC 0.78% 1,587,890 -26% 0.75% $25,596,787
Woodline Partners LP 0.74% 1,498,725 0% 0.11% $24,159,447
GOLDMAN SACHS GROUP INC 0.73% 1,482,539 +24% 0% $23,898,528
Aberdeen Group plc 0.48% 981,804 +16% 0.03% $15,826,680
CITADEL ADVISORS LLC 0.37% 746,553 +113% 0.01% $12,034,434
UBS Group AG 0.36% 726,173 +8.2% 0% $11,705,908
Prosight Management, LP 0.34% 698,472 +46% 2.7% $11,259,369
BNP PARIBAS FINANCIAL MARKETS 0.34% 683,402 0% 0.01% $11,016,440
Pictet Asset Management Holding SA 0.33% 676,577 -43% 0.01% $10,906,421
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.29% 580,696 -12% 0% $9,360,820

Institutional Holders of Immunovant, Inc. - Common Stock, par value $0.0001 per share (IMVT) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q4 251,563 $6,394,359 -$425,596 $25.42 4
2025 Q3 95,141,975 $1,533,691,024 -$22,917,430 $16.12 181
2025 Q2 96,203,927 $1,539,273,430 +$25,954,256 $16.00 167
2025 Q1 94,088,777 $1,608,317,726 +$221,642,111 $17.09 191
2024 Q4 80,137,358 $1,984,988,003 -$10,994,227 $24.77 186
2024 Q3 79,205,377 $2,259,063,728 +$130,270,111 $28.51 182
2024 Q2 74,718,656 $1,972,484,501 +$94,283,095 $26.40 195
2024 Q1 70,316,923 $2,271,922,665 +$28,234,974 $32.31 208
2023 Q4 68,405,672 $2,881,981,571 +$25,897,847 $42.13 227
2023 Q3 68,143,903 $2,616,088,544 +$461,829,770 $38.39 179
2023 Q2 55,460,743 $1,051,890,599 -$33,129,073 $18.97 145
2023 Q1 58,264,079 $903,668,302 +$20,897,901 $15.51 140
2022 Q4 56,538,511 $1,003,523,628 +$261,143,310 $17.75 132
2022 Q3 42,668,627 $238,077,080 +$13,851,662 $5.58 107
2022 Q2 40,117,493 $156,470,492 +$2,266,222 $3.90 87
2022 Q1 39,493,605 $217,710,240 -$1,326,202 $5.51 108
2021 Q4 37,845,291 $322,423,547 -$6,093,696 $8.52 118
2021 Q3 33,769,857 $293,475,463 -$50,043,046 $8.69 115
2021 Q2 38,555,821 $407,535,405 -$67,673,203 $10.57 110
2021 Q1 40,251,421 $645,603,475 -$273,082,395 $16.04 118
2020 Q4 40,331,237 $1,862,979,798 +$41,257,802 $46.19 146
2020 Q3 39,828,501 $1,401,617,459 +$384,378,297 $35.19 116
2020 Q2 28,564,750 $695,567,285 +$388,041,409 $24.35 87
2020 Q1 12,628,676 $193,544,419 +$19,992,364 $15.56 40
2019 Q4 11,331,532 $175,598,863 +$163,278,863 $15.87 24